Carotid Stent Market Size
The Carotid Stent Market size was valued at USD 336 million in 2021 and is estimated to reach at a CAGR of 7.20% over the forecast period 2024-2031. Carotid stents are the medical devices placed in the carotid artery to remove the plaque formed. Stents placed in the carotid artery decrease the risk of stroke by widening the narrowed carotid artery and thus regulating a continuous blood flow.
North America held the global market share due to factors such as the large population base, growing prevalence of cardiovascular diseases, and rising adoption of advanced technologies. For instance, Adopting a sedentary lifestyle has severe implications for people's health and is known to cause diseases related to cardiovascular diseases, obesity, high blood pressure, etc. According to the World Health Organization, around about 60% - 85% of people worldwide have adopted a sedentary life.
According to the Centre for Disease Control and Prevention, around 31 million adults aged over 50 years lives a sedentary life, and only 1 out of 4 U.S. adults & 1 out of five school student meets the guideline for physical activity. Heart disease is one of most leading causes of death in the U.S.; at least one person dies every 37 seconds due to cardiovascular disease, as reported by the Centre for Disease Control and Prevention. North American governments are taking measures to improve healthcare outcomes and reduce hospital expenditures; the adoption of advanced high-end technologies, world-class infrastructure, and awareness regarding drug therapies are helping to expand the market in this region.
Market Summary
| Metrics | Details |
| Market CAGR | 7.20% |
| Segments Covered | By Material, By Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Download Sample
Market Dynamics
The carotid stent market growth is driven by the rise in prevalence of diseases such as cardiovascular diseases, the growing geriatric population with bypass surgery, rising adoption of minimally invasive procedures, the surge in research and development initiatives for heart diseases, and increasing technological advancements are the major factors driving the carotid stents market.
Increasing technological advancements are expected to drive the global carotid stent market growth
For a considerable time, stents have been used as a part of coronary and peripheral procedures in many countries to avoid or neutralize the narrowing and hindering of vessels. The utilization of these stents has been effective; they are not without downsides and concerns. Restenosis, or the reoccurrence of vessel narrowing after the interventional procedure, is a typical symptom of a body's normal reaction to a foreign particle in the vasculature.
The drug-eluting stents (DES) result in better clinical outcomes by reducing the risk of restenosis significantly. New improvements in DES, such as biodegradable and bifurcated stents, are required to increase the market value of a company. Organizations like Biosensors and Abbott create biodegradable and bifurcated stents to manage issues of thrombosis, which is caused by long-term device implantation.
Rising demand for minimally invasive procedures is expected to drive the global carotid stent market growth
The demand for minimally invasive procedures has been rapidly increasing globally. MI procedures reduce the physical injury risk and the chances of an infection, thereby enabling patients to have a more convenient and quicker recovery. MI procedures have certain advantages, such as affordable cost and shorter hospital stays. These methods have shown better outcomes than traditional methods.
MI procedures for heart diseases involve the insertion of delicate instruments through a small incision. Patients treated with these technologies can expect lesser discomfort and scarring and quicker recuperation than conventional surgeries. MI procedures have helped in the effective management of a few infections. These have also allowed specialists to make substantially smaller incisions.
Stringent approval processes is likely to hinder the market growth
Approval processes in many of the counties are very stringent for carotid stents. As these are to be introduced in the body, they fall under Class II and III devices, and it involves lots of time and investment for the approval of stent systems. For instance, recently, Boston Scientific SYNERGY Stent gained PMA approval after years of clinical trials. According to Advanced Medical Technology Association, it is estimated that about 77% and 80% of the total cost incurred in bringing a class II and class III medical device, respectively, to market is spent on FDA-linked approval stages.
Complications associated with stents is likely to hamper the market growth
According to the European Society of Cardiology, the potential procedural and peri-procedural complications that may be related to carotid angioplasty and stenting may be categorized as minor or major complications, including
Carotid artery spasm, Sustained, hypotension/bradycardiaCarotid artery dissection, Contrast encephalopathy (infrequent), and Minor embolic neurological events (TIAs) are the major complications, and minor complications like Major embolic stroke, Intracranial hemorrhage, Hyperperfusion syndrome, Carotid perforation (very rare), Acute stent thrombosis (very rare), Complications at the site of the vascular access.
COVID-19 Impact On Carotid Stent Market
The COVID-19 pandemic continues to endanger global health and hinder the world economy; It has been widely observed that patients with existing cardiovascular diseases experience higher complications due to COVID-19. Specifically, it has been found that patients with hypertension, diabetes and other comorbidities are at higher risk of death from the virus. During the widespread COVID-19 pandemic, there have been worries about the potential of specific procedures.
The Centers for Disease Control and Prevention (CDC) and the European Society of Cardiology (ESC), and its council on hypertension have released position statements saying “we should not be jumping to conclusions and should not be withholding life-saving therapies from patients.” More importantly, two very recent studies attest that blood pressure drugs and their associated minimally invasive procedures do not increase coronavirus risk. Some of these factors are driving the market growth in the forecast period.
Market Segmentation Analysis
The self-expanding stents segment is expected to hold the largest share in this market segment
Self-expanding stents (SE) are of high elasticity but apply low radial outward force, allowing them to regain their shape after the compression force reduces, and have higher trackability, thus are easier to maneuver through tortuous vessels or pass the aortic bifurcation from the contralateral approach. For instance, Abbott conducting a study (superiority trial) to compare the Supera Peripheral Stent System with a standard nitinol self-expanding stent for treatment of femoropopliteal arterial occlusive disease is expected to be complete by 2023.
The nitinol segment is expected to hold the largest share in this market segment
The nitinol segment served the largest share of the market. Nitinol also known as nickel-titanium alloy, contains nearly an equal amount of nickel and titanium. Therefore, it has significant applications in medical devices where its unique properties allow minimally invasive surgery and implants to improve the quality of life for people. Moreover, its significant properties, such as nonmagnetic, corrosion resistance, biocompatible, and heat resistance, better flexibility have further boosted the market growth.
The most widely used material for self-expandable stents is nitinol. Self-expandable stents are advantageous because minor damage to the vessel is caused by low pressure while the stent is dilated. Moreover, self-expandable stents are beneficial for complex lesions as they can be securely implanted without using a balloon.
The hospital segment is expected to hold the largest share in this market segment
The hospital segment held the largest share in the carotid stent market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Also, the demand for products like carotid stents from these hospitals is increasing due to the rising awareness about the benefits of leading a better and healthy life. Moreover, the growing number of hospitals along with adequate reimbursement policies are also contributing to the growth of this segment.
Companies and Competitive Landscape
The global carotid stent market is highly competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Boston Scientific Corporation, Cardinal Health, Medtronic Plc, Terumo Corporation, MicroPort Scientific Corporation, W. L. Gore & Associates, BIOTRONIK SE & Co. KG, InspireMD, and Impulse Dynamics, Shanghai Hengfei Biological Technology Co., Ltd., Beijing Bomais Technology Development, Shanghai Zhenyu Biological Technology Co., Ltd, Shanghai Haoran Biotechnology Co., Ltd.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, On May 3, 2021, Medtronic Announced the CE Mark of Evolut™ PRO+ TAVI System for the Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe. In the Evolut platform design, the PRO+ valve is designed with a self-expanding nitinol frame that conforms to the native annulus with consistent radial force and advanced sealing.
Key Companies to Watch
Boston Scientific Corporation
Overview: The company was founded in 1979. It has headquarters in the United States. It develops, manufactures, and markets minimally invasive medical devices. The Company's products are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation. Globally the company has business in the US, EMEA, Asia-Pacific, Latin America, and Canada.
Product Portfolio: The company works through the segments MedSurg which include Endoscopy, Urology, and Pelvic Health, Rhythm and Neuro, Cardiovascular, and Specialty pharmaceuticals.
Product: The REBEL Stent System is the newest advance in bare-metal stent technology. REBEL Stent has the visibility you want from its PtCr alloy, the strength that needs with the lowest recoil* and greatest radial strength, and the outstanding deliverability.
Key Developments: On Nov 2, 2020, Boston Scientific announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
